Indaptus Therapeutics Inc (INDP) Stock Analysis
Verdict: AVOID
Massive selling shareholder overhang and a sub-12-month cash runway make recent technical strength a likely exit window for insiders.
Investment score: 32/100
Analysis as of
Is Indaptus Therapeutics Inc stock worth reviewing? AI model thesis
INDP is a high-risk biotech microcap with deteriorating liquidity and significant insider selling pressure.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Indaptus Therapeutics Inc opportunities and risks
What speaks for INDP
- Phase I Decoy20 Data
What speaks against INDP
- Massive Equity Overhang
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INDP | n/a | 0.0x | n/a | 0.0% | 0.0% | -9.7% |
| HUMA | n/a | 54.0x | n/a | -666.8% | -4560.8% | -85.2% |
| VYGR | n/a | 5.8x | n/a | -104.2% | -312.6% | -60.5% |
| CUE | n/a | 1.7x | n/a | 99.7% | -435.8% | -77.6% |
| NKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -53.1% |
| CRBU | n/a | 15.9x | n/a | -129.7% | -1030.4% | -60.0% |
| Peer median | n/a | 5.8x | n/a | -104.2% | -435.8% | -60.5% |
Frequently asked questions about Indaptus Therapeutics Inc (INDP)
Is INDP stock a good investment?
The cached TradeMates AI model rates Indaptus Therapeutics Inc as AVOID with an investment score of 32/100. INDP is a high-risk biotech microcap with deteriorating liquidity and significant insider selling pressure. This is algorithmic model output, not personal investment advice.
Is INDP stock a buy?
The TradeMates model verdict for INDP is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.